| Naslov: | Comparative outcomes of GH treatment in pediatric idiopathic short stature and GH deficiency |
|---|
| Avtorji: | ID Phillip, Moshe (Avtor)
ID Abuzzahab, M. Jennifer (Avtor)
ID Pietropoli, Alberto (Avtor)
ID Ferran, Jean-Marc (Avtor)
ID Højby Rasmussen, Michael (Avtor)
ID Kelepouris, Nicky (Avtor)
ID Kotnik, Primož (Avtor)
ID Polak, Michel (Avtor)
ID Sävendahl, Lars (Avtor) |
|---|
| Datoteke: |  PDF - Predstavitvena datoteka, prenos (931,74 KB)
MD5: 0A3453D0A80353B2046A17766FB8E5D3
 URL - Izvorni URL, za dostop obiščite https://academic.oup.com/jes/article/9/10/bvaf133/8236488
|
|---|
| Jezik: | Angleški jezik |
|---|
| Tipologija: | 1.01 - Izvirni znanstveni članek |
|---|
| Organizacija: |  UKC LJ - Univerzitetni klinični center Ljubljana
|
|---|
| Povzetek: | Context: GH treatment in children with idiopathic short stature (ISS) can be controversial, and analyses comparing responses to children with GH deficiency (GHD) are limited. Objective: To compare the effectiveness and safety of GH treatment in children with ISS and GHD, including those reaching near adult height (NAH). Methods: This post hoc analysis of the NordiNet International Outcome Study (2006-2016) and the American Norditropin Studies: Web-Enabled Research Program (2002-2016) included children with ISS or GHD who initiated treatment aged <18 years. The safety analysis set had birthdate and GH exposure information. The effectiveness analysis set was GH-naïve with valid baseline information. GH exposure, effectiveness, and safety outcomes were analyzed annually for ≤10 years. Results: The safety analysis set included 3816 children with ISS and 22 858 with GHD. The effectiveness analysis set comprised 18 405 children (ISS: 2684; GHD: 15 721), 1856 of whom reached NAH (ISS: 230; GHD: 1626). Average dose of GH was higher for children with ISS vs children with GHD but mean duration of treatment was shorter. At NAH, height SD score (mean [SD]) was −1.21 (1.09) and −0.90 (1.20) for children with ISS and GHD, respectively, whereas change in height SD score (mean [SD]) from baseline to 10 years was 1.21 (0.86) and 1.45 (1.09). Incidence of adverse reactions was similar across indications, with no new safety signals. Conclusion: GH treatment over 5 to 10 years effectively increased height in children with ISS and children with GHD, including those who reached NAH, with a favorable benefit-risk profile. |
|---|
| Ključne besede: | comparative outcomes, growth hormon treatment, growth hormon deficiency, pediatrics |
|---|
| Status publikacije: | Objavljeno |
|---|
| Verzija publikacije: | Objavljena publikacija |
|---|
| Leto izida: | 2025 |
|---|
| Št. strani: | str. 1-10 |
|---|
| Številčenje: | Vol. 9, issue 10 |
|---|
| PID: | 20.500.12556/DiRROS-28719  |
|---|
| UDK: | 616-053.2 |
|---|
| ISSN pri članku: | 2472-1972 |
|---|
| DOI: | 10.1210/jendso/bvaf133 |
|---|
| COBISS.SI-ID: | 273655811 |
|---|
| Opomba: | Nasl z nasl. zaslona;
Opis vira z dne 31. 3. 2026;
|
|---|
| Datum objave v DiRROS: | 31.03.2026 |
|---|
| Število ogledov: | 182 |
|---|
| Število prenosov: | 102 |
|---|
| Metapodatki: |    |
|---|
|
:
|
Kopiraj citat |
|---|
| | | | Objavi na: |  |
|---|
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše
podrobnosti ali sproži prenos. |
